Quarterly Appendix 4C Cash Flow Report
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The report indicates net cash used in operating activities, with significant payments for research and development and staff costs. The financing activities section shows proceeds from equity securities, contributing to a net cash increase for the period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Syntara
- Quarterly Shareholder Report
- New positive interim data in Phase 2 study of SNT-5505
- SNT-5505 awarded US FDA Fast Track designation
- Quarterly Activities Report
- Acceleration of skin scarring program
Later from Syntara
- Suspension from Quotation
- Reinstatement to Quotation
- Guidance from FDA on amsulostat clinical progression
- Preliminary Final Report
- Positive top-line Phase 2a data confirms competitive profile
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara